Press release
Recurrent or Metastatic Head and Neck cancer Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and Companies
Stay ahead with the latest insights! Download DelveInsight's comprehensive Recurrent or Metastatic Head and Neck Cancer Pipeline Report to explore emerging therapies, key companies, and future treatment landscapes @ Recurrent or Metastatic Head and Neck Cancer Pipeline Outlook [https://www.delveinsight.com/sample-request/recurrent-or-metastatic-head-and-neck-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Recurrent or Metastatic Head and Neck Cancer Pipeline Report
* On 19 August 2025, Bicara Therapeutics announced a study intends to evaluate the safety and efficacy of ficerafusp alfa in combination with pembrolizumab versus placebo with pembrolizumab in 1L PD-L1-positive, recurrent or metastatic Head and Neck Squamous Cell Carcinoma (HNSCC).
* On 17 August 2025, Exelixis conducted a Phase 2/3 trial of zanzalintinib in combination with pembrolizumab versus zanzalintinib-matched placebo in combination with pembrolizumab in subjects with programmed death-ligand 1 (PD-L1) positive recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) incurable by local therapies who have not received prior systemic therapy for recurrent or metastatic disease.
* DelveInsight's Recurrent or Metastatic Head and Neck Cancer pipeline report depicts a robust space with 40+ active players working to develop 40+ pipeline therapies for Recurrent or Metastatic Head and Neck Cancer treatment.
* The leading Recurrent or Metastatic Head and Neck Cancer Companies such as Eisai Co Ltd, Sinocelltech, Merck, Nanobiotix, Sichuan Baili Pharmaceutical, Adlai Nortye Biopharma, BioNTech, PDS Biotechnology, Shanghai Miracogen, Incyte Corporation, Checkmate Pharmaceuticals, NATCO Pharma, Agenus, Jiangsu Hengrui Medicine, Cue Biopharma, AbbVie and others.
* Promising Recurrent or Metastatic Head and Neck Cancer Therapies such as docetaxel (XRP6976), cisplatin, 5-fluorouracil (5-FU), Pemetrexed, Cetuximab, Carboplatin , and others.
Discover how the Recurrent or Metastatic Head and Neck Cancer treatment paradigm is evolving. Access DelveInsight's in-depth pipeline Analysis for a closer look at promising breakthroughs @ Recurrent or Metastatic Head and Neck Cancer Clinical Trials and Studies [https://www.delveinsight.com/sample-request/recurrent-or-metastatic-head-and-neck-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Recurrent or Metastatic Head and Neck Cancer Emerging Drugs Profile
* Xevinapant: Merck
Xevinapant is the first Inhibitor of Apoptosis Proteins antagonist with FDA Breakthrough Therapy Designation for previously untreated locally advanced squamous cell carcinoma of the head and neck, in combination with current standard of care. Merck gains exclusive global development and commercialization rights; Debiopharm to receive 188 million upfront and up to 710 million in regulatory and commercial milestones, as well as royalty payments
* SI B001: Sichuan Baili Pharmaceutical
SI B001 is a bispecific antibody designed with the proprietary platform technology developed by Baili and SystImmune. It can bind to EGFR and HER3, and simultaneously inhibits the ligand induced EGFR times EGFR homodimers, the formation of EGFR times HER3 heterodimers and the activation of its downstreamsignal pathway. SI-B001 can also induce endocytosis of EGFR and HER3, anddown-regulate the levels of EGFR and HER3 tumor cells. In preclinical studies, SI-B001 has demonstrated superior tumor killing activities. SI-B001 Phase I trials have shown good safety and preliminary efficacy.
The Recurrent or Metastatic Head and Neck Cancer pipeline report provides insights into
* The report provides detailed insights about companies that are developing therapies for the treatment of Recurrent or Metastatic Head and Neck Cancer with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Recurrent or Metastatic Head and Neck Cancer Treatment.
* Recurrent or Metastatic Head and Neck Cancer Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Recurrent or Metastatic Head and Neck Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Recurrent or Metastatic Head and Neck Cancer market.
Get a detailed analysis of the latest innovations in the Recurrent or Metastatic Head and Neck Cancer pipeline. Explore DelveInsight's expert-driven report today! @ Recurrent or Metastatic Head and Neck Cancer Unmet Needs [https://www.delveinsight.com/sample-request/recurrent-or-metastatic-head-and-neck-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Recurrent or Metastatic Head and Neck Cancer Companies
Eisai Co Ltd, Sinocelltech, Merck, Nanobiotix, Sichuan Baili Pharmaceutical, Adlai Nortye Biopharma, BioNTech, PDS Biotechnology, Shanghai Miracogen, Incyte Corporation, Checkmate Pharmaceuticals, NATCO Pharma, Agenus, Jiangsu Hengrui Medicine, Cue Biopharma, AbbVie and others.
Recurrent or Metastatic Head and Neck cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
* Oral
* Intravenous
* Subcutaneous
Recurrent or Metastatic Head and Neck Cancer Products have been categorized under various Molecule types such as
* Small molecule
* Cell Therapy
* Peptides
* Polymer
* Small molecule
* Gene therapy
Download DelveInsight's latest report to gain strategic insights into upcoming Recurrent or Metastatic Head and Neck Cancer Therapies and key developments @ Recurrent or Metastatic Head and Neck Cancer Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/recurrent-or-metastatic-head-and-neck-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Recurrent or Metastatic Head and Neck Cancer Pipeline Report
* Coverage- Global
* Recurrent or Metastatic Head and Neck Cancer Companies- Eisai Co Ltd, Sinocelltech, Merck, Nanobiotix, Sichuan Baili Pharmaceutical, Adlai Nortye Biopharma, BioNTech, PDS Biotechnology, Shanghai Miracogen, Incyte Corporation, Checkmate Pharmaceuticals, NATCO Pharma, Agenus, Jiangsu Hengrui Medicine, Cue Biopharma, AbbVie and others.
* Recurrent or Metastatic Head and Neck Cancer Therapies- docetaxel (XRP6976), cisplatin, 5-fluorouracil (5-FU), Pemetrexed, Cetuximab, Carboplatin , and others.
* Recurrent or Metastatic Head and Neck Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Recurrent or Metastatic Head and Neck Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Which companies are leading the race in Recurrent or Metastatic Head and Neck Cancer drug development? Find out in DelveInsight's exclusive pipeline Report-access it now! @ Recurrent or Metastatic Head and Neck Cancer Emerging Drugs and Major Companies [https://www.delveinsight.com/sample-request/recurrent-or-metastatic-head-and-neck-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Content
* Introduction
* Executive Summary
* Recurrent or Metastatic Head and Neck cancer: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Recurrent or Metastatic Head and Neck cancer- DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* Lenvatinib: Eisai Co
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* SI B001: Sichuan Baili Pharmaceutical
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* Revdofilimab: AbbVie
* Drug profiles in the detailed report.....
* Early Stage Products (Preclinical)
* Drug name: Company name
* Drug profiles in the detailed report.....
* Inactive Products
* Recurrent or Metastatic Head and Neck cancer Key Companies
* Recurrent or Metastatic Head and Neck cancer Key Products
* Recurrent or Metastatic Head and Neck cancer- Unmet Needs
* Recurrent or Metastatic Head and Neck cancer- Market Drivers and Barriers
* Recurrent or Metastatic Head and Neck cancer- Future Perspectives and Conclusion
* Recurrent or Metastatic Head and Neck cancer Analyst Views
* Recurrent or Metastatic Head and Neck cancer Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=recurrent-or-metastatic-head-and-neck-cancer-pipeline-outlook-2025-clinical-trial-studies-ema-pdma-fda-approvals-moa-roa-nda-ind-and-companies]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/recurrent-or-metastatic-head-and-neck-cancer-pipeline-insight
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Recurrent or Metastatic Head and Neck cancer Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and Companies here
News-ID: 4158909 • Views: …
More Releases from ABNewswire
Avansaber Launches AI-Powered SAP Utilities ERP to Revolutionize Digital Operati …
How Artificial Intelligence Accelerates SAP Utilities ERP Projects for Smarter Grid Management and Enhanced Customer Experiences
AUSTIN, TX - August 25, 2025 - As the global energy sector navigates the complexities of decarbonization, grid modernization, and rising customer expectations, the role of technology has never been more critical. At the forefront of this transformation is the integration of Artificial Intelligence (AI) into core operational systems. For utility companies leveraging SAP, AI…
Travel Experts Reveal the Only Way to Travel in Luxury to Antarctica
Antarctica remains one of the most remote and pristine destinations on Earth - and now, explorers can discover it in complete luxury.
"I've never met anyone who's returned from Antarctica unchanged," says polar explorer and adventurer Ben Saunders, standing beside a striking image of himself at the South Pole, flashing two thumbs up. "It's truly mind-blowing."
This sentiment is shared by countless travelers who have journeyed to the "white desert." Being surrounded…
Usemultiplier Publishes Review-Based Analysis on Whether Deel Is the Right Fit f …
Global hiring is no longer limited to enterprises with massive legal teams. Even small and mid-sized companies now build distributed teams using digital tools. But one challenge stays constant, how do you employ people legally in a country where you don't have an office? That's where Employer of Record (EOR) platforms come into the picture.
EOR services act as a bridge between global employers and local compliance. They help businesses onboard…
Nomad Internet Launches RecycleNomad.com - The First ISP That Pays Customers to …
Image: https://www.abnewswire.com/upload/2025/08/f40bb60637a5fe9df1b4517af8fe7151.jpg
Austin, TX - Nomad Internet, the nation's largest rural wireless internet provider, today announced the launch of RecycleNomad.com [http://recyclenomad.com/], a groundbreaking new initiative that pays customers real cash for returning old Nomad modems. In a first-of-its-kind program for the internet service industry, Nomad is turning equipment returns into an opportunity for customers to earn money, reduce waste, and support rural families who need internet access.
From Fees to Cash Rewards:…
More Releases for Head
Green Dot Sign® Going Head-to-Head with Traditional Plastic ADA Signs
After the success of their groundbreaking sustainable ADA compliant interior signs, Green Dot Sign® is now offering a more affordable and adaptable option than ever before: Low profile office signs.
Nussbaum started considering environmentally-friendly manufacturing methods and products while working at his prior sign company. The idea to create signage from a wood base and non-toxic 3D printed material for lettering, braille, and pictograms was sparked by a braille sign with…
China and India are growing head to head in Companion Diagnostic market
“Asia-Pacific Companion Diagnostics Market" research report, published by Market Data Forecast estimates that the market is growing with a CAGR of 27.91% to reach USD 2.17 billion by 2021, from USD 0.63 billion in 2016, which amounts to a cumulative growth of USD 1.54 billion.
A companion diagnostics device is a medical device that provides information which is necessary for drug safety and effectives or any other biological product. This helps…
East and West going head to head in Asia-Pacific Food Emulsifiers Market
Asia-Pacific Food Emulsifiers Market" research report, published by Market Data Forecast delineates that the market is growing with a CAGR of 6.15% to reach USD 0.78 billion by 2021, from USD 0.58 billion in 2016, which amounts to a cumulative growth of USD 0.20 billion.
View Full Report at http://www.marketdataforecast.com/market-reports/asia-pacific-food-emulsifiers-market-564/
Download Free Sample report at http://www.marketdataforecast.com/market-reports/asia-pacific-food-emulsifiers-market-564/request-sample
A substance used in food manufacturing which helps to combine liquids of different thicknesses is known as…
dinCloud Earns Top Marks in Head-to-Head Comparison
The #1 Brand in Hosted Virtual Desktops
LOS ANGELES, CA – June 19, 2012 – dinCloud, a cloud transformation company and provider of hosted virtual desktops, has come out on top as the leading provider of DaaS (Desktop as a Service) in a head-to-head comparison of five market leaders by ExtremeLabs. dinCloud’s solution received the groupings highest marks for the solution’s good control, as well as fast response, and was the…
University Students go head to head in University of Bolton’s “Sports Fiesta …
The University of Bolton Student’s Council and the Student Activities Department organized an integrated program of sporting activities around the theme "Sports Fiesta 2012" which drew a number of Universities from the Northern Emirates and Dubai.
The activities took place at UOB RAK Campus. Separate activities for male and female attendees included; badminton, basketball, chess, cricket, darts, tug-o-war, sprint race, football and volleyball matches, and other recreational games.
To coincide with the…
KnowledgetoAction Departments Go Head to Head in a Bowling Competition
London, UK ( ) October 25, 2010 - Employees of KnowledgetoAction (http://knowledgeandaction.co.uk) have been going head to head against each other in a series of team building competitions that began on September 1, 2010. Knowledge to Action believes strongly in team building and this event showcased their desire for excellent team cooperation and communication between departments, allowing for more cohesiveness within Knowledge to Action.
Most recently, each of the KnowledgetoAction…
